Tags

Type your tag names separated by a space and hit enter

A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia.
Hum Psychopharmacol. 2014 Jan; 29(1):83-8.HP

Abstract

OBJECTIVE

This study was a comparative investigation of the clinical efficacy and safety of intramuscular (IM) olanzapine, IM haloperidol, and IM levomepromazine in acute agitated patients with schizophrenia.

METHODS

The subjects were 122 inpatients. Their clinical symptoms were assessed using Positive and Negative Syndrome Scale Excited Component (PANSS-EC), PANSS, and Agitation-Calmness Evaluation Scale, and their safety were assessed using the Abnormal Involuntary Movement Scale, Barnes Akathisia Rating Scale (BARS), and Drug-induced Extrapyramidal Symptoms Scale (DIEPSS).

RESULTS

The mean changes from baseline on the PANSS-EC, Agitation-Calmness Evaluation Scale, Abnormal Involuntary Movement Scale, BARS, and DIEPSS scores were significantly better in both IM olanzapine and IM levomepromazine than in IM haloperidol. Of these, the mean changes from baseline on the BARS and DIEPSS scores were significantly better in IM olanzapine than in IM levomepromazine. The mean change from baseline on the PANSS positive score was significantly better in both IM olanzapine and IM haloperidol than in IM levomepromazine.

CONCLUSIONS

The results of this study suggest the possibility that the anti-agitation effects of IM olanzapine and IM levomepromazine are more rapid than those of IM haloperidol. No worsening of EPS was observed. Our results also suggest that compared with IM levomepromazine, IM olanzapine is safer and affords greater improvement in symptoms.

Authors+Show Affiliations

Department of Psychiatry, Suzuki Clinic, Tokyo, Japan.No affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

24424709

Citation

Suzuki, Hidenobu, et al. "A Naturalistic Comparison Study of the Efficacy and Safety of Intramuscular Olanzapine, Intramuscular Haloperidol, and Intramuscular Levomepromazine in Acute Agitated Patients With Schizophrenia." Human Psychopharmacology, vol. 29, no. 1, 2014, pp. 83-8.
Suzuki H, Gen K, Takahashi Y. A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia. Hum Psychopharmacol. 2014;29(1):83-8.
Suzuki, H., Gen, K., & Takahashi, Y. (2014). A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia. Human Psychopharmacology, 29(1), 83-8. https://doi.org/10.1002/hup.2376
Suzuki H, Gen K, Takahashi Y. A Naturalistic Comparison Study of the Efficacy and Safety of Intramuscular Olanzapine, Intramuscular Haloperidol, and Intramuscular Levomepromazine in Acute Agitated Patients With Schizophrenia. Hum Psychopharmacol. 2014;29(1):83-8. PubMed PMID: 24424709.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia. AU - Suzuki,Hidenobu, AU - Gen,Keishi, AU - Takahashi,Yuki, PY - 2013/06/07/received PY - 2013/11/08/revised PY - 2013/11/11/accepted PY - 2014/1/16/entrez PY - 2014/1/16/pubmed PY - 2014/9/16/medline KW - efficacy KW - intramuscular haloperidol KW - intramuscular levomepromazine KW - intramuscular olanzapine KW - safety SP - 83 EP - 8 JF - Human psychopharmacology JO - Hum Psychopharmacol VL - 29 IS - 1 N2 - OBJECTIVE: This study was a comparative investigation of the clinical efficacy and safety of intramuscular (IM) olanzapine, IM haloperidol, and IM levomepromazine in acute agitated patients with schizophrenia. METHODS: The subjects were 122 inpatients. Their clinical symptoms were assessed using Positive and Negative Syndrome Scale Excited Component (PANSS-EC), PANSS, and Agitation-Calmness Evaluation Scale, and their safety were assessed using the Abnormal Involuntary Movement Scale, Barnes Akathisia Rating Scale (BARS), and Drug-induced Extrapyramidal Symptoms Scale (DIEPSS). RESULTS: The mean changes from baseline on the PANSS-EC, Agitation-Calmness Evaluation Scale, Abnormal Involuntary Movement Scale, BARS, and DIEPSS scores were significantly better in both IM olanzapine and IM levomepromazine than in IM haloperidol. Of these, the mean changes from baseline on the BARS and DIEPSS scores were significantly better in IM olanzapine than in IM levomepromazine. The mean change from baseline on the PANSS positive score was significantly better in both IM olanzapine and IM haloperidol than in IM levomepromazine. CONCLUSIONS: The results of this study suggest the possibility that the anti-agitation effects of IM olanzapine and IM levomepromazine are more rapid than those of IM haloperidol. No worsening of EPS was observed. Our results also suggest that compared with IM levomepromazine, IM olanzapine is safer and affords greater improvement in symptoms. SN - 1099-1077 UR - https://www.unboundmedicine.com/medline/citation/24424709/A_naturalistic_comparison_study_of_the_efficacy_and_safety_of_intramuscular_olanzapine_intramuscular_haloperidol_and_intramuscular_levomepromazine_in_acute_agitated_patients_with_schizophrenia_ L2 - https://doi.org/10.1002/hup.2376 DB - PRIME DP - Unbound Medicine ER -